Study to Assess Batoclimab in Participants With Active Thyroid Eye Disease
Status:
Not yet recruiting
Trial end date:
2025-01-01
Target enrollment:
Participant gender:
Summary
To evaluate the efficacy of batoclimab 680 milligrams (mg) subcutaneous (SC) once a week (QW)
for 12 weeks followed by 340 mg SC QW for 12 weeks versus placebo on proptosis responder rate
at Week 24.